0001104659-23-098985.txt : 20230907
0001104659-23-098985.hdr.sgml : 20230907
20230907170014
ACCESSION NUMBER: 0001104659-23-098985
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230907
FILED AS OF DATE: 20230907
DATE AS OF CHANGE: 20230907
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Khattar Jack A.
CENTRAL INDEX KEY: 0001539937
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 231242950
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060317
4
1
tm2325321-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-09-07
0
0001356576
SUPERNUS PHARMACEUTICALS, INC.
SUPN
0001539937
Khattar Jack A.
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
ROCKVILLE
MD
20850
1
1
0
0
President, CEO
0
Common Stock
2023-09-07
4
M
0
35000
0
A
884267
D
Common Stock
2023-09-07
4
F
0
16804
32.10
D
867463
D
Common Stock
1038950
I
By the KBT Trust
Performance Share Unit
0
2023-09-07
4
M
0
35000
0
D
Common Stock
35000
0
D
Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023.
Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting.
On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.
/s/ Timothy C. Dec, as attorney-in-fact
2023-09-07